PL3037101T3 - Terapia antagonistą receptora oksytocyny w fazie lutealnej w celu implantacji i uzyskania ciąży u kobiet poddawanych technikom wspomaganego rozrodu - Google Patents

Terapia antagonistą receptora oksytocyny w fazie lutealnej w celu implantacji i uzyskania ciąży u kobiet poddawanych technikom wspomaganego rozrodu

Info

Publication number
PL3037101T3
PL3037101T3 PL14199709T PL14199709T PL3037101T3 PL 3037101 T3 PL3037101 T3 PL 3037101T3 PL 14199709 T PL14199709 T PL 14199709T PL 14199709 T PL14199709 T PL 14199709T PL 3037101 T3 PL3037101 T3 PL 3037101T3
Authority
PL
Poland
Prior art keywords
pregnancy
implantation
receptor antagonist
luteal phase
oxytocin receptor
Prior art date
Application number
PL14199709T
Other languages
English (en)
Inventor
Joan-Carles Arce
Original Assignee
Ferring B.V.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ferring B.V. filed Critical Ferring B.V.
Publication of PL3037101T3 publication Critical patent/PL3037101T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B17/00—Surgical instruments, devices or methods
    • A61B17/42—Gynaecological or obstetrical instruments or methods
    • A61B17/425—Gynaecological or obstetrical instruments or methods for reproduction or fertilisation
    • A61B17/435—Gynaecological or obstetrical instruments or methods for reproduction or fertilisation for embryo or ova transplantation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/095—Oxytocins; Vasopressins; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/06—Antiabortive agents; Labour repressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Reproductive Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Surgery (AREA)
  • Gynecology & Obstetrics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pregnancy & Childbirth (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Molecular Biology (AREA)
  • Transplantation (AREA)
  • Biomedical Technology (AREA)
  • Medical Informatics (AREA)
  • Dermatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
PL14199709T 2014-12-22 2014-12-22 Terapia antagonistą receptora oksytocyny w fazie lutealnej w celu implantacji i uzyskania ciąży u kobiet poddawanych technikom wspomaganego rozrodu PL3037101T3 (pl)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP14199709.8A EP3037101B1 (en) 2014-12-22 2014-12-22 Oxytocin receptor antagonist therapy in the luteal phase for implantation and pregnancy in women undergoing assisted reproductive technologies

Publications (1)

Publication Number Publication Date
PL3037101T3 true PL3037101T3 (pl) 2019-06-28

Family

ID=52338895

Family Applications (1)

Application Number Title Priority Date Filing Date
PL14199709T PL3037101T3 (pl) 2014-12-22 2014-12-22 Terapia antagonistą receptora oksytocyny w fazie lutealnej w celu implantacji i uzyskania ciąży u kobiet poddawanych technikom wspomaganego rozrodu

Country Status (21)

Country Link
US (4) US9579305B2 (pl)
EP (2) EP3501533B1 (pl)
JP (2) JP6858130B2 (pl)
KR (1) KR102715569B1 (pl)
CN (2) CN107249618B (pl)
AU (1) AU2015367900B2 (pl)
BR (1) BR112017013521A2 (pl)
CA (1) CA2971846A1 (pl)
CL (1) CL2017001640A1 (pl)
EA (1) EA201791361A1 (pl)
ES (2) ES2716862T3 (pl)
IL (1) IL253078B (pl)
MX (1) MX374877B (pl)
MY (1) MY181349A (pl)
PH (1) PH12017550030B1 (pl)
PL (1) PL3037101T3 (pl)
SG (1) SG11201705175RA (pl)
TW (1) TWI702043B (pl)
UA (1) UA125492C2 (pl)
WO (1) WO2016105190A1 (pl)
ZA (1) ZA201704958B (pl)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2845850A1 (en) 2013-09-10 2015-03-11 ObsEva S.A. Pyrrolidine derivatives as oxytocin/vasopressin V1a receptors antagonists
EP2886107A1 (en) 2013-12-17 2015-06-24 ObsEva S.A. Oral formulations of pyrrolydine derivatives
CN114105851A (zh) 2014-07-02 2022-03-01 奥布赛瓦股份公司 治疗ot-r活性相关的病症的方法中可用的晶体
ES2716862T3 (es) 2014-12-22 2019-06-17 Ferring Bv Terapia con antagonistas del receptor de oxitocina en la fase lútea para la implantación y embarazo en mujeres que se someten a tecnologías de reproducción asistida
LT3400217T (lt) 2016-01-04 2022-06-27 Merck Serono S.A. Hidroksipropiltiazolidino karboksamido l-valinato darinys, jo druska ir jo kristalinė forma
WO2018015497A2 (en) * 2016-07-21 2018-01-25 ObsEva S.A. Oxytocin antagonist dosing regimens for promoting embryo implantation and preventing miscarriage
AU2020340670A1 (en) 2019-09-03 2022-04-07 ObsEva S.A. Oxytocin antagonist dosing regimens for promoting embryo implantation and preventing miscarriage
WO2021160597A1 (en) 2020-02-10 2021-08-19 ObsEva S.A. Biomarkers for oxytocin receptor antagonist therapy
JPWO2022091809A1 (pl) * 2020-10-28 2022-05-05
CN114292907A (zh) * 2020-12-15 2022-04-08 苏州亿康医学检验有限公司 用于反复植入失败的生物标志物和诊断与治疗方法
CN117531006B (zh) * 2023-10-10 2025-02-11 山东奥克斯畜牧种业有限公司 一种提高牛胚胎移植受胎率的组合制剂及其制备方法与应用

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9604341D0 (sv) * 1996-11-26 1996-11-26 Ferring Bv Hepta-peptide oxytocin analogue
AUPP421298A0 (en) 1998-06-19 1998-07-09 Fertilitescentrum Ab Method and medium for in vitro culture of human embryos
ATE367817T1 (de) * 2001-01-09 2007-08-15 Bayer Schering Pharma Ag Verwendung von antigestagene zur verschiebung der endometrialen reifung wahrend infertilitätbehandlung
PT1425033E (pt) * 2001-09-12 2010-12-29 Merck Serono Sa Utilização de hcg e lh na hiper-estimulação controlada dos ovários
AU2003211011A1 (en) 2002-02-27 2003-09-09 Ferring Bv Intermediates and methods for making heptapeptide oxytocin analogues
UA78058C2 (en) * 2002-07-05 2007-02-15 Applied Research Systems Pyrrolidine derivative as oxitocin antagonists
GB0219961D0 (en) 2002-08-28 2002-10-02 Pfizer Ltd Oxytocin inhibitors
FR2849380A1 (fr) * 2002-12-27 2004-07-02 Ernest Loumaye NOUVELLE UTILISATION D'UN AGONISTE DU GnRH
US7111275B2 (en) 2003-08-28 2006-09-19 International Business Machines Corporation Electronic circuit design analysis system
US20070276019A1 (en) 2003-09-18 2007-11-29 Axys Pharmaceuticals, Inc. Haloalkyl Containing Compounds as Cysteine Protease Inhibitors
EP1673355A1 (en) 2003-09-22 2006-06-28 Pfizer Limited Substituted triazole derivatives as oxytocin antagonists
EP1555029A1 (en) 2004-01-19 2005-07-20 Ferring B.V. Use of substances having oxytocin antagonistic properties for the preparation of a medicament for treating hypertension
KR100985449B1 (ko) * 2005-05-10 2010-10-05 페링 인터내셔널 센터 에스 에이 옥시톡신 및/또는 바소프레신 길항제의 용도
WO2010010201A1 (es) 2008-07-22 2010-01-28 Equipo Ivi Investigacion Sl Perfil de expresion genetica como marcador de la receptividad endometrial
AU2010246918A1 (en) 2009-05-14 2011-12-01 Adelaide Research & Innovation Pty Ltd Methods for the collection and maturation of oocytes
US9481863B2 (en) 2011-07-01 2016-11-01 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for determining developmental stage of human cumulus cells
US10271876B2 (en) 2011-11-23 2019-04-30 Mezadata Medical Ip Holding Llc Method of in vitro fertilization with delay of embryo transfer and use of peripheral blood mononuclear cells
US20130337487A1 (en) 2012-05-31 2013-12-19 Auxogyn, Inc. In vitro embryo blastocyst prediction methods
US20160278688A1 (en) 2012-11-26 2016-09-29 Ferring B.V. Method and System for Diagnosing Uterine Contraction Levels Using Image Analysis
ES2716862T3 (es) 2014-12-22 2019-06-17 Ferring Bv Terapia con antagonistas del receptor de oxitocina en la fase lútea para la implantación y embarazo en mujeres que se someten a tecnologías de reproducción asistida

Also Published As

Publication number Publication date
EP3037101B1 (en) 2019-03-06
US20170189415A1 (en) 2017-07-06
JP6858130B2 (ja) 2021-04-14
US11752157B2 (en) 2023-09-12
CA2971846A1 (en) 2016-06-30
IL253078A0 (en) 2017-08-31
PH12017550030A1 (en) 2018-01-15
US10183029B2 (en) 2019-01-22
CN107249618B (zh) 2021-11-16
MY181349A (en) 2020-12-21
US10688106B2 (en) 2020-06-23
MX2017008455A (es) 2018-04-26
AU2015367900B2 (en) 2021-05-13
UA125492C2 (uk) 2022-04-13
ES2716862T3 (es) 2019-06-17
EP3037101A1 (en) 2016-06-29
EP3501533A1 (en) 2019-06-26
US9579305B2 (en) 2017-02-28
TW201636016A (zh) 2016-10-16
SG11201705175RA (en) 2017-07-28
MX374877B (es) 2025-03-06
US20170348325A1 (en) 2017-12-07
NZ733869A (en) 2020-10-30
EP3501533B1 (en) 2025-07-09
BR112017013521A2 (pt) 2018-03-06
US20160175283A1 (en) 2016-06-23
KR102715569B1 (ko) 2024-10-11
PH12017550030B1 (en) 2024-07-03
EA201791361A1 (ru) 2017-11-30
WO2016105190A1 (en) 2016-06-30
CN107249618A (zh) 2017-10-13
CL2017001640A1 (es) 2018-01-26
IL253078B (en) 2020-04-30
CN113940990A (zh) 2022-01-18
KR20170135821A (ko) 2017-12-08
AU2015367900A1 (en) 2017-08-03
TWI702043B (zh) 2020-08-21
ES3041573T3 (en) 2025-11-13
JP7184935B2 (ja) 2022-12-06
US20200352962A1 (en) 2020-11-12
JP2021054863A (ja) 2021-04-08
ZA201704958B (en) 2019-10-30
JP2018505212A (ja) 2018-02-22

Similar Documents

Publication Publication Date Title
ZA201704958B (en) Oxytocin receptor antagonist therapy in the luteal phase for implantation and pregnancy in women undergoing assisted reproductive technologies
IL250362A0 (en) A chimeric anti-cd123 antigen receptor for cancer therapy
GB201600635D0 (en) Anchor for inplantation in body tissue
SG11201702611YA (en) Combination therapy for use in cancer therapy
PT3311168T (pt) Nova estrutura de tnf para utilização em terapia
HUE044823T2 (hu) Õssejtterápia méhnyálkahártya-patológiákban
GB201403969D0 (en) Compounds for use in controlling body fat
GB201702160D0 (en) Inhibitors for use in therapy
PL3140545T3 (pl) Zintegrowana jednostka do zastosowania w stacji pomp
IL248855A0 (en) S-pyralindole and its pharmaceutically acceptable salts for use in medicine
IL231278A0 (en) A system to assist a needy person in transitioning between standing and sitting and between sitting and standing
SG11201802956RA (en) Colloidal particles for use in medicine
IL248854B (en) R-pyralindole and its pharmaceutically acceptable salts for use in medicine
GB201615844D0 (en) Agents for use in therapy
PT3592184T (pt) Conjunto para utilização na preparação de uma bebida por meio de um dispositivo de preparação de bebidas
IL252043A0 (en) A proline-rich polypeptide complex for use in the treatment of brain neurotrophic factor-related disorders
PL3278941T3 (pl) Przyrząd do montażu na sucho płyt gipsowo-kartonowych
GB201617451D0 (en) Polypeptides for use in therapy
GB201516723D0 (en) Polypeptides for use in therapy
GB201416493D0 (en) Polypeptides for use in therapy
GB201707861D0 (en) Methods for improving mitophagy in subjects
GB201707863D0 (en) Methods for improving mitophagy in subjects
GB201706596D0 (en) Methods for improving mitophagy in subjects
ZA201501073B (en) Device for improving resting comfort of a person in transit
GB201703735D0 (en) Methods for improving mitophagy in subjects